According to the National Health Commission, further efforts will be made to ensure the use of drugs for children, promote the research and development, creation, and application review of suitable varieties, dosage forms, and specifications for children, and meet the clinical medication needs of pediatrics. The National Health Commission, in conjunction with the Ministry of Science and Technology, the Ministry of Industry and Information Technology, the National Medical Insurance Bureau, and the National Drug Administration, will organize expert selection and social publicity to develop the "Fourth Batch of Encouraged Research and Application List of Children's Drugs". The fourth batch of lists has 24 varieties, involving 30 product specifications and 9 dosage forms, covering treatment fields such as nervous system drugs, gastrointestinal and metabolic drugs, anti-tumor drugs, and immune modulators. To ensure the smooth implementation of encouraging the research and development of children's drugs, the National Health Commission will collaborate with the Ministry of Science and Technology, the Ministry of Industry and Information Technology, the National Medical Insurance Administration, and the National Drug Administration to further increase the support for research and development of children's drugs and the construction of related industry projects. Priority will be given to the review and approval of encouraging the research and development of children's drugs, According to the procedures, encourage the development and application of children's drugs that meet the conditions to be included in the national essential drug catalog and the national basic medical insurance drug catalog, guide the improvement of China's comprehensive research and development level of children's drugs, promote the rational and standardized use of children's drugs, and support the supply of children's drugs to ensure high-quality development.